Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 12/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 10/20 | 0.40 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delafloxacin SCHEMBL294694 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL29356726 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL29631821 | 0.99 | CYP3A4 (0.85) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL441203 | 0.99 | CYP3A4 (0.85) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL7248671 | 0.96 | CYP3A4 (0.82) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30626293 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL29080648 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL29080643 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30626258 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30593852 | 0.93 | CYP3A4 (0.75) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3957632-A1 | MEGLUMINE SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG (DELAFLOXACIN) | AbbVie Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| CN-116514775-B | New crystal form of meglumine salt of DELASHANXIA and preparation method thereof | 安徽普利药业有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-12138257-B2 | Antimicrobial compositions | MELINTA SUBSIDIARY CORP. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240307368-A1 | ANTIMICROBIAL COMPOSITIONS | MELINTA THERAPEUTICS, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240165100-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | MELINTA SUBSIDIARY CORP. | 2024-05-23 | — | — | US | disclosed |
| CN-114831955-B | Use of a pharmaceutical composition for the preparation of a medicament for the treatment, prevention or reduction of the risk of a bacterial infection | 梅琳塔有限责任公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117185995-A | 3, 5-difluoropyridine-2, 6-diamine derivative, preparation method and preparation method of 3, 5-difluoropyridine-2, 6-diamine | 上海凌凯医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-116514775-A | New crystal form of meglumine salt of DELASHANXIA and preparation method thereof | 海南普利制药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-107778293-B | Improved preparation method of delafloxacin | 鲁南制药集团股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-114031607-B | Refining method of delafloxacin and intermediate thereof | 海南普利制药股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220265636-A1 | ANTIMICROBIAL COMPOSITIONS | MELINTA SUBSIDIARY CORP. | 2022-08-25 | — | — | US | disclosed |
| CN-114831955-A | Use of a pharmaceutical composition for the manufacture of a medicament for treating, preventing, or reducing the risk of bacterial infection | 梅琳塔有限责任公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-106572982-B9 | Antimicrobial compositions with effervescent agents | 梅琳塔有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-106572982-B | Antimicrobial compositions with effervescent agents | 梅琳塔有限责任公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114539213-A | Fluoroquinolone compound and preparation method and application thereof | 广东工业大学 | 2022-05-27 | — | — | CN | disclosed |
| EP-3957632-A1 | MEGLUMINE SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG (DELAFLOXACIN) | AbbVie Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-114031607-A | Refining method of delafloxacin and intermediate thereof | 海南普利制药股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265636-A1 | ANTIMICROBIAL COMPOSITIONS | NOD2, QPCT, IFNG | CYP3A4 545/4885CYP2C9 402/4885ALDH1A1 2608/4885 |
| US-20240307368-A1 | ANTIMICROBIAL COMPOSITIONS | NOD2, QPCT, IFNG | CYP3A4 545/4885CYP2C9 402/4885ALDH1A1 2608/4885 |
| US-20240165100-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | CLPP, MGAM, MMP8 | CYP3A4 2192/4885CYP2C9 1889/4885ALDH1A1 2778/4885 |
| US-12138257-B2 | Antimicrobial compositions | NOD2, QPCT, IFNG | CYP3A4 545/4885CYP2C9 402/4885ALDH1A1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.